Holding News
Heading: Aspen increases revenue 16% to R41.2 bn
Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, has announced pleasing results for the year ended 30 June 2017. Download (PDF 86.7KB) […]
Read MoreAspen AstraZeneca Anaesthetics Portfolio Agreement
Aspen Holdings is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has signed an agreement with AstraZeneca AB and AstraZeneca UK (“AstraZeneca”) whereby AGI will acquire the exclusive rights to commercialise AstraZeneca’s global (excluding the USA) anaesthetics portfolio (“the Transaction”). AstraZeneca’s anaesthetics portfolio comprises seven established medicines, namely Diprivan (general anaesthesia),…
Read MoreAspen demonstrates economic growth and specialized technologies contributions to Deputy President Cyril Ramaphosa
Port Elizabeth. JSE-listed Aspen, the largest pharmaceutical manufacturer in the southern hemisphere, earlier today hosted Deputy President Cyril Ramaphosa and Minister of Health Dr Aaron Motsoaledi at its Port Elizabeth-based flagship manufacturing site. The visit provided an opportunity to discuss Aspen’s economic growth and export contributions to South Africa, and to demonstrate its globally recognised…
Read MoreAspen’s profit after tax increases by 35%
Aspen Pharmacare Holdings Limited (“Aspen”) (Incorporated in the Republic of South Africa) (Registration Number 1985/002935/06) (Share code APN ISIN: ZAE000066692) Aspen’s profit after tax increases by 35% Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical manufacturer in the southern hemisphere, has announced pleasing results for the six months ended 31…
Read MoreDivestment of portfolio of branded and generic products to Strides entities
21/05/15: Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen Australia”), have entered into an agreement with Strides (Australia) Pharma Pty Ltd (“Strides Australia”), a company incorporated in Australia, in terms whereof Aspen Australia will divest to Strides Australia, a portfolio of approximately 130 products for a consideration of…
Read MoreCautionary Announcement
14/05/15: Shareholders are advised that Aspen is currently engaged in discussions regarding a possible acquisition of an infant nutritionals business. These discussions may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to exercise caution when dealing in the Company’s securities. Durban 14 May 2015 Sponsor …
Read MoreDivestment of South African Business Unit to Litha
11/05/15: Aspen is pleased to announce that Pharmacare Limited (“Pharmacare”), a wholly owned subsidiary of Aspen Holdings and the Group’s primary South African trading company, has concluded a set of agreements with Litha Pharma (Pty) Ltd (“Litha”) (a wholly owned South African subsidiary of Endo International Plc) in terms which Pharmacare will divest a business…
Read MoreGauteng Premier’s visit to Aspen is set to boost export growth
07/05/15: Clayville, Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the 5th largest generic company in the world, earlier today hosted a delegation of over 30 government dignitaries at its manufacturing facility where specialised infant nutritional products are produced for local and export markets. The facility is unique in that it contains highly…
Read MoreAspen opposes violent attacks directed at fellow African migrants
28/04/15: Statement by Stephen Saad, Group CEO, Aspen Pharmacare Holdings Ltd “Aspen” on the violent attacks directed at fellow African migrants living in South Africa Durban – Aspen, largest producer and supplier of medicines to our African continent, in the strongest terms condemns the shameful and senseless harassment and violence directed at fellow African migrants,…
Read MoreGSK announces completion of the sale of half its stake in Aspen
13/03/15: GlaxoSmithKline (“GSK”) has announced the completion of the disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares). These shares were sold by means of an accelerated book build offering process which resulted in the shares being sold at ZAR 372 per share, raising gross proceeds of approximately ZAR…
Read More